We were able to use the PSD protein signature of AD + P to computationally nominate several novel potential pharmacotherapies for the treatment of AD + P, and provide initial experimental validation that administration of one of the nominated drugs, maraviroc, to adult mice yielded a net reversal of the PSD protein signature of AD + P. The gene discussed is PSD; the disease is Alzheimer disease.